Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “clostridium”

25 pharma patents match "clostridium" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 25
Index total 30,257
Page 1 / 2

Quick answer

This filtered view shows 25 pharmaceutical patents matching "clostridium" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

25 results for “clostridium” · 30,257 patents in full index Clear search

  1. US 2025235515

    CLOSTRIDIUM BOTULINUM NEUROTOXIN SEROTYPE A COMPOSITIONS AND IMPROVED DRYING PROCESSES

    ABBVIE INC [US] · Granted Jul 24, 2025 · Expires Jul 19, 2045

    granted

  2. WO 2025111258

    COMPOSITIONS DE SÉROTYPE A DE NEUROTOXINE DE CLOSTRIDIUM BOTULINUM ET PROCÉDÉS DE FILTRATION AMÉLIORÉS

    ABBVIE INC [US] · Granted May 30, 2025 · Expires May 25, 2045

    granted

  3. US 12257235

    Methods and materials for using ruminococcus gnavus or clostridium sporogenes to treat gastrointestinal disorders

    The Regents of the University of California · Granted Mar 25, 2025 · Expires Mar 20, 2045

    granted

  4. US 12144800

    Inhibiting germination of Clostridium perfringens spores to reduce necrotic enteritis

    THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS · Granted Nov 19, 2024 · Expires Nov 14, 2044

    granted

  5. US 11878002

    Methods and materials for using Ruminococcus gnavus or Clostridium sporogenes to treat gastrointestinal disorders

    The Regents of the University of California · Granted Jan 23, 2024 · Expires Jan 18, 2044

    granted

  6. US 11730775

    Methods for treatment of Clostridium difficile infection or recurrence or symptoms thereof

    Seres Therapeutics, Inc. · Granted Aug 22, 2023 · Expires Aug 17, 2043

    granted

  7. US 11118170

    Engineered clostridium botulinum toxin adapted to deliver molecules into selected cells

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Sep 14, 2021 · Expires Sep 9, 2041

    granted

  8. US 10993930

    Methods and materials for using Ruminococcus gnavus or Clostridium sporogenes to treat gastrointestinal disorders

    The Regents of the University of California · Granted May 4, 2021 · Expires Apr 29, 2041

    granted

  9. US 10945996

    Inhibiting germination of clostridium perfringens spores to reduce necrotic enteritis

    THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS · Granted Mar 16, 2021 · Expires Mar 11, 2041

    granted

  10. US 10933126

    Clostridium difficile immunogenic compositions and methods of use

    The Board of Regents of the University of Oklahoma · Granted Mar 2, 2021 · Expires Feb 25, 2041

    granted

  11. WO 2021005497

    ANTAGONISTES DU CGRP ET DÉRIVÉS DE CLOSTRIDIUM POUR LE TRAITEMENT DE TROUBLES ASSOCIÉS À LA DÉPRESSION CORTICALE ENVAHISSANTE

    ALLERGAN PHARMACEUTICALS INT LTD [IE] · Granted Jan 14, 2021 · Expires Jan 9, 2041

    granted

  12. US 10709758

    Peptide inhibitors of clostridium difficile toxin B (TcdB) toxin

    The Board of Regents of the University of Oklahoma · Granted Jul 14, 2020 · Expires Jul 9, 2040

    granted

  13. US 10669242

    Clostridium difficile toxin inhibitors

    VENENUM BIODESIGN, LLC · Granted Jun 2, 2020 · Expires May 28, 2040

    granted

  14. US 10633643

    Engineered Clostridium botulinum toxin adapted to deliver molecules into selected cells

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Apr 28, 2020 · Expires Apr 23, 2040

    granted

  15. US 10544406

    Characterization of four prophage endolysins specific for clostridium perfringens

    The United States of America, as represented by the Secretary of Agriculture · Granted Jan 28, 2020 · Expires Jan 23, 2040

    granted

  16. CA 3105778

    POLYTHERAPIE AVEC DES ANTAGONISTES DU CGRP ET DES DERIVES DE CLOSTRIDIUM

    ALLERGAN PHARMACEUTICALS INT LTD [IE] · Granted Jan 9, 2020 · Expires Jan 4, 2040

    granted

  17. US 10286054

    Attenuated EHEC and clostridial toxins TcdA and TcdB based vaccine for Clostridium difficil associated disease (CDAD)

    United States Government as represented by the Department of Veterans Affairs · Granted May 14, 2019 · Expires May 9, 2039

    granted

  18. US 10226523

    Clostridium difficile vaccine and methods of use

    The Board of Regents of the University of Oklahoma · Granted Mar 12, 2019 · Expires Mar 7, 2039

    granted

  19. US 9446112

    Clostridium difficile DNA vaccine

    Inovio Pharmaceuticals, Inc. · Granted Sep 20, 2016 · Expires Sep 15, 2036

    granted

  20. US 9399674

    Human antibodies to Clostridium difficile toxins

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 26, 2016 · Expires Jul 21, 2036

    granted

  21. US 9278091

    Compounds for the treatment of Clostridium difficile associated disease

    SUMMIT THERAPEUTICS PLC · Granted Mar 8, 2016 · Expires Mar 3, 2036

    granted

  22. US 8987308

    Compounds for the treatment of Clostridium difficile-associated disease

    Summit Corporation Plc · Granted Mar 24, 2015 · Expires Mar 19, 2035

    granted

  23. US 7226597

    Mutants of Clostridium difficile toxin B and methods of use

    The Board of Regents of the University of Oklahoma · Granted Jun 5, 2007 · Expires May 31, 2027

    granted

  24. US 7179888

    Antigenic, non-toxic mutants of Clostridium septicum alpha toxin and vaccines, antibodies, sera, and methods of treatment therewith

    The Board of Regents of the University of Oklahoma · Granted Feb 20, 2007 · Expires Feb 15, 2027

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.